PledPharma approved for listing on Nasdaq Stockholm

PledPharma AB (publ) today announced that Nasdaq Stockholm's Listing Committee has decided to approve PledPharma AB (publ)'s shares for trading on the main market of Nasdaq Stockholm. The approval is subject to customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority, supplemented with the company's financial report for the first nine months of the year.

First day of trading on Nasdaq Stockholm's main market is scheduled for October 31, 2019 and the last day of trading on Nasdaq First North Growth Market is scheduled for October 30, 2019. The shares will be traded under the same ticker (PLED) and ISIN-code (SE0003815604). There is no fund raising or new share issue in connection with the list change, and shareholders in PledPharma do not need to take any actions.

"The listing on Nasdaq Stockholm's main market is a natural step in the company's development that reflects the maturity of our business and which increases awareness of the company. Being listed on a regulated market, PledPharma also becomes more accessible and attractive to both Swedish and foreign institutional investors," said Nicklas Westerholm, CEO of PledPharma.

For further information, please refer to the prospectus that has been prepared for the change of list, which is expected to be approved by the Swedish Financial Supervisory Authority and published on PledPharma's website in good time before the first day of trading on Nasdaq Stockholm. The company's interim report for January – September 2019 will be published on October 23, 2019.

Pareto Securities AB and Advokatfirman Lindahl KB are PledPharma's financial and legal advisers respectively, in connection with the listing.

Contacts

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO, phone: +46 72 231 68 00
yilmaz.mahshid@pledpharma.se

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company's Certified Adviser (tel +46 8 463 83 00, certifiedadviser@penser.se). For more information, see http://www.pledpharma.com/

This information is information that PledPharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2019-10-16 15:55 CEST.

Attachments

PledPharma approved for listing on Nasdaq Stockholm